Patents by Inventor Thomas D. Ingolia
Thomas D. Ingolia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150038459Abstract: Nutritious protein-containing foodstuffs can be prepared in the form of gels, including protein gel and fruit purees that contain all essential amino acids. A protein gel for use as a foodstuff is prepared by heating an aqueous protein solution to between 160 and 185 degrees Fahrenheit at an acidic pH between 2.85 and 3.5, the protein solution having a viscosity greater than 100 centipoise and containing a protein at a concentration of 10-20% w/w, the protein being at least one of a whey protein isolate and a liquid soy protein isolate, the protein gel having a viscosity of between 10,000 and 1,000,000 centipoise.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: Michelle Bacarella, Steven A. Rittmanic, Thomas D. Ingolia
-
Publication number: 20110311682Abstract: Nutritious protein-containing foodstuffs can be prepared in the form of gels, including protein gel and fruit purees that contain all essential amino acids. A protein el for use as a foodstuff is prepared by heating an aqueous protein solution to between 160 and 185 degrees Fahrenheit at an acidic pH between 2.85 and 3.5, the protein solution having a viscosity greater than 100 centipoise and containing a protein at a concentration of 10-20% w/w, the protein being at least one of a whey protein isolate and a liquid soy protein isolate, the protein gel having a viscosity of between 10,000 and 1,000,000 centipoise.Type: ApplicationFiled: February 24, 2010Publication date: December 22, 2011Applicant: NUTRIFAM, LLCInventors: Michelle Bacarella, Steven A. Rittmanic, Thomas D. Ingolia
-
Patent number: 6180361Abstract: The present invention provides DNA compounds that encode the expandase/hydroxylase enzyme of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a variety of host cells, including E. coli, Penicillium, and Cephalosporium.Type: GrantFiled: December 12, 1988Date of Patent: January 30, 2001Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud
-
Patent number: 5196524Abstract: Novel fusion reporter genes, fusion reporter proteins, and an improved reporter system for measuring the relative activity of a promoter sequence. A luxAB fusion gene of the present invention is particularly useful as a reporter gene and is derived from the fusion of a luxA gene and a luxB gene from Vibrio harveyi. The gene products of the luxA and luxB genes are the .alpha.- and .beta.-subunits, respectively, of a bacterial luciferase. A fusion protein encoded by a luxAB fusion gene is a single active protein and is particularly useful as a reporter protein having luciferase activity. An advantage of such a reporter system to assay gene expression in many cells which contain FMNH.sub.2, such as bacterial and yeast cells, is that an immediate and quantitative assessment of gene expression may be made from real-time light measurements using intact cells.Type: GrantFiled: January 6, 1989Date of Patent: March 23, 1993Assignee: Eli Lilly and CompanyInventors: Gary D. Gustafson, Thomas D. Ingolia, Gretchen Kirchner, Jean L. Roberts
-
Recombinant DNA expression vectors and DNA compounds that encode deacetoxycephalosporin C synthetase
Patent number: 5070020Abstract: The present invention provides DNA compounds that encode deacetoxycephalosporin C synthetase (DAOCS) activity. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Streptomyces, Aspergillus, and Cephalosporium.Type: GrantFiled: May 9, 1988Date of Patent: December 3, 1991Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Steven Kovacevic, James R. Miller, Paul L. Skatrud -
Patent number: 4960704Abstract: A modified hygromycin B resistance-conferring gene either alone or in translational reading phase with a gene or portion of a gene is disclosed. The invention further comprises recombinant DNA cloning vectors and transformants of the aforementioned DNA.Type: GrantFiled: May 31, 1988Date of Patent: October 2, 1990Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Kevin R. Kaster, R. Nagaraja Rao
-
Patent number: 4950603Abstract: DNA compounds encoding the Streptomyces lipmanii isopenicillin N synthetase (IPNS) gene are useful for constructing a variety of recombinant DNA vectors. The vectors are useful in producing IPNS in a wide variety of host cells, such as Streptomyces, Penicillium, and Cephalosporium. DNA compounds encoding the transcription and translation activating sequence and transcription termination sequence of the S. lipmanii IPNS gene are also useful in the construction of expression vectors, especially Streptomyces expression vectors. The S. lipmanii IPNS gene can be isolated from plasmid pOGO239, available from the Northern Regional Research Center under accession number NRRL B-18250.Type: GrantFiled: November 2, 1987Date of Patent: August 21, 1990Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Barbara J. Weigel
-
Patent number: 4902620Abstract: The present invention is a novel method for maintaining and selecting recombinant DNA-containing host cells wherein the DNA encoding a selectable phenotype and the DNA encoding a useful polypeptide are the same. The aforementioned DNA is useful for expressing .delta.-aminolevulinic acid synthetase (ALAS) for the ultimate expression of .delta.-aminolevulinic acid (ALA) in yeast and related organisms. The invention further comprises plasmids pIT300, pIT301, pIT302, pIT304, pIT305, pIT306 and related Saccharomyces ALA deficient transformants. ALA is a five carbon amino acid that is useful as a light dependent herbicide.Type: GrantFiled: April 25, 1985Date of Patent: February 20, 1990Assignee: Eli Lilly and CompanyInventors: Martin Bard, Thomas D. Ingolia
-
Patent number: 4892819Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase. The invention also comprises methods, transformants, and polypeptides related to the novel DNA compounds. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcription and translation activating sequence, was isolated from Penicillium chrysogenum. The isopenicillin N synthetase-encoding DNA can be used to construct novel E. coli expression vectors that drive expression of isopenicillin N synthetase in E. coli. The intact P. chrysogenum isopenicillin N synthetase-encoding DNA and associated transcription and translation activating sequence can also be used to construct expression vectors that drive expression of the isopenicillin N synthetase in P. chrysogenum and Cephalosporium acremonium. The transcription and translation activating sequence can be fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto expression vectors that function in P. chrysogenum and C.Type: GrantFiled: November 25, 1985Date of Patent: January 9, 1990Assignee: Eli Lilly and CompanyInventors: Lucinda G. Carr, Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud
-
Patent number: 4885251Abstract: The present invention comprises novel DNA compounds that encode isopenicillin N synthetase and also comprises related methods, transformants, and polypeptides. The novel isopenicillin N synthetase-encoding DNA, together with its associated transcriptional and translational activating sequence, was isolated from Cephalosporium acremonium and cloned into an E. coli cloning vector. The isopenicillin N synthetase-encoding DNA has been used to construct novel E. coli expression vectors that drive expression of a stable, active, and novel isopenicillin N synthetase in E. coli. The intact C. acremonium isopenicillin N synthetase-encoding DNA and associated transcriptional and translational activating sequence have also been used to construct C. acremonium expression vectors that drive expression of the isopenicillin N synthetase in C. acremonium. The C. acremonium transcriptional and translational activating sequence has further been fused to a hygromycin phosphotransferase-encoding DNA segment and placed onto C.Type: GrantFiled: August 8, 1986Date of Patent: December 5, 1989Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Suellen M. Samson, Paul L. Skatrud, Otis W. Godfrey
-
Patent number: 4885252Abstract: DNA compounds and recombinant DNA expression vectors that encode and drive expression in recombinant host cells of the isopenicillin N synthetase activity of Aspergillus nidulans are useful to produce isopenicillin N synthetase and to improve the yield of .beta.-lactam-containing antibiotics from antibiotic-producing organisms. The isopenicillin N synthetase gene of A. nidulans can be isolated from plasmid pOGOO4, available from the Northern Regional Research Center under the accession number NRRL B-18171.Type: GrantFiled: December 14, 1987Date of Patent: December 5, 1989Assignee: Eli Lilly and CompanyInventors: Thomas D. Ingolia, Stephen W. Queener, Paul L. Skatrud, Barbara J. Wiegel
-
Patent number: 4762786Abstract: A method for transforming Cephalosporium and other lower eukaryotes is disclosed. The method involves inserting a recombinant DNA cloning vector comprising a Saccharomyces cerevisiae transcriptional and translational activating sequence positioned for expression of hygromycin phosphotransferase into a host cell and then growing the host cell under selective conditions. The vectors optionally further comprise Cephalosporium ribosomal DNA and also sequences that allow for replication and selection in E. coli and Streptomyces.Type: GrantFiled: September 27, 1984Date of Patent: August 9, 1988Assignee: Eli Lilly and CompanyInventors: Jerry L. Chapman, Jr., Thomas D. Ingolia, Kevin R. Kaster, Stephen W. Queener, Paul L. Skatrud
-
Patent number: 4745057Abstract: Disclosed are a novel method for inducing the high expression of a nucleotide sequence which is under the transcriptional and translational control of the yeast YG100 gene and the novel vectors, transformants and selectable DNA for the practice thereof.Type: GrantFiled: August 13, 1984Date of Patent: May 17, 1988Assignee: Eli Lilly and CompanyInventors: Cheryl A. Beckage, Thomas D. Ingolia
-
Patent number: 4559302Abstract: The present invention relates to a novel transcriptional and translational activating sequence. The novel activating sequence can be either chemically synthesized or isolated on a 0.17 kb PstI-SacI restriction fragment from plasmid pKC203, a plasmid of E. coli JR225 (ATCC 31912). The activating sequence directs expression of the aminoglycoside acetyltransferase aac(3)IV and hygromycin phosphotransferase aph(4) genes present on plasmid pKC203. A series of expression vectors have been constructed in which the activating sequence directs the expression of beta-galactosidase or hygromycin phosphotransferase. These vectors can be readily modified and have been designed to facilitate the subsequent cloning and expression of any gene of research or commercial interest. The expression and cloning vectors have been transformed into E. coli and other host cells in which the activating sequence functions.Type: GrantFiled: November 1, 1982Date of Patent: December 17, 1985Assignee: Eli Lilly and CompanyInventor: Thomas D. Ingolia